Spherix Incorporated, announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose® (D-tagatose), in the treatment and management of Type 2 diabetes.
>more»

Spherix Incorporated, announced that it has received its first full-scale production batch of cGMP (FDA Current Good Manufacturing Practice) D‑tagatose, USP (U.S. Pharmacopeia) grade.  One metric ton of drug was received from the manufacturer, Inalco S.p.A., of Italy.  Spherix will use the tagatose in the process of satisfying the CMC (Chemistry, Manufacturing and Control) requirements of its NDA (New Drug Application) to the U.S. FDA. 
>more»

Spherix Incorporated, announced that it has terminated the 1996 license agreement pursuant to which it granted Arla Foods Ingredients Amba (“Arla”) the food and beverage rights to D-tagatose.
>more»

Spherix Incorporated, announced that it has fully regained compliance with all requirements for continued listing on the NASDAQ Capital Market.
>more»

Spherix Incorporated reported results for the first quarter ended March 31, 2009. 
>more»

Spherix Incorporated announced that it will exhibit at the 2009 BIO International Conference in Atlanta, Georgia on May 18-21, 2009. 
>more»

Spherix Incorporated announced that, on May 12, 2009, its Board of Directors elected a new, independent Director, Thomas B. Peter, to begin serving immediately.  Mr. Peter will also serve on the Company’s Compensation and Nominating Committees. 
>more»

Spherix announced that on April 23, 2009, it received written notification from NASDAQ that the Company was not currently in compliance with NASDAQ’s independent director rule. 
>more»

Spherix announces the death of A. Paul Cox, JR., Chairman of the Board
>more»

Spherix holds 2008 earnings conference call
>more»

Spherix reported results for the year ended December 31, 2008.
>more»

Spherix announced the postponement of its 2009 Annual Shareholders Meeting.
>more»

Spherix Stockholders Authorize Potential Reverse Stock Split
>more»
 
Spherix Reports 3rd Quarter Earnings
>more»
 
Spherix Transfers Stock Listing To Nasdaq Capital Market
>more»
 
Patient Recruitment Begins In India For Phase 3 Diabetes Trial
>more»
 
Spherix Receives NASDAQ Letter Extending Minimum Bid Price Compliance Period
>more»
 
Spherix Incorporated To Seek Stockholder Approval Of Reverse Stock Spilt
>more»
 
Spherix Reports 2nd Quarter Earnings
>more»
 
Spherix Receives NASDAQ Bid Price Deficiency Letter
>more»